Best Life Sciences Platforms and Tools Companies in Australia
The 105 best Life Sciences Platforms and Tools companies in Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Inventia Life Science.
Tracking the best Life Sciences Platforms and Tools companies in Australia, this directory ranks 105 ventures by disclosed equity funding and recent momentum, and the numbers tell a focused story. Total disclosed funding sits at $191M across the cohort, with Inventia Life Science leading at $50M, Cynata close behind at $32M, and PolyActiva and SUDA Pharmaceuticals each at $24M. No unicorns yet, but the spread of active backers, Brandon Capital, Uniseed, Yuuwa Capital, and Cicada Innovations, signals a maturing ecosystem rather than a one-bet sector. The global market was valued at roughly $89.4B in 2020 and is forecast to reach $183.8B by 2027 at a 10.8% CAGR, driven by advances in MS resolution, quantitative accuracy, and information sciences.
So where's the pressure? Regulatory challenges remain the structural friction point, slowing commercialisation timelines for tools that are technically ready. I'd note that digital adoption is accelerating in parallel, with median app install growth running at roughly 43% year-on-year across life sciences and healthcare platforms, which tells you demand-side appetite is real. As shown in 2010 research, foundational genomic tooling underpins much of what today's platforms are building on. You're looking at a sector that's capital-constrained relative to its global peers, but directionally very much in motion this quarter.
- ResearchAndMarkets.com
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Australia
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Inventia Life Science Developer of 3D bio-printers | $50M | 48 mo ago | Series B | 90 | Aidan O'Mahony Co-Founder & CTO | HubSpot CMS HubApple iCloud MailMicrosoft 365+19 | 43 patents 3D bioprinting hardware and processes for fabricating tissue constructs | — |
| 2 | Cynata Stem cell and regenerative medicine company developing a platform for off-the-shelf production of Mesenchymal… | $32M | 44 mo ago | Public | 2 | — | — | — | — |
| 3 | SUDA Pharmaceuticals Developer of oro-mucosal drug delivery technology for treating multiple diseases | $24M | 60 mo ago | Public | — | Stephen Carter Chairman & CEO | — | 7 patents Anti‑metastatic therapies targeting platelet‑mediated cancer progression | — |
| 4 | PolyActiva Drug delivery platform | $24M | 12 mo ago | Series C | 27 | — | — | — | — |
| 5 | Elastagen Company offering solutions for cell growth and tissue repair through their Elastin technology | $15M | 116 mo ago | Acquired | 5 | — | — | — | — |
| 6 | Genetic Signatures Molecular diagnostic reagents and kits for pathogen detection | $11M | 117 mo ago | Public | — | — | WordPressApple iCloud MailMySQL+26 | 166 patents Isothermal nucleic acid amplification and molecular detection of microbial genetic material | 4 job openings |
| 7 | Paragen Bio Developer of biologics for the treatment of autoimmune diseases | $6M | 94 mo ago | Deadpooled | — | Norelle Daly Co-Founder | — | — | — |
| 8 | Cincera Therapeutics Drug discovery platform | $6M | 100 mo ago | Series A | 3 | Stuart Pitson Co-Founder | — | 13 patents Patents concentrated in chemistry & materials | — |
| 9 | Phoenix Biosystem Developer of biomarker panels and assays for disease assessment and detection | $4M | 73 mo ago | Funding Raised | — | Kumar Subramanian CEO and Co-Founder | — | — | — |
| 10 | Nexgen Plants Provider of platform technology for developing virus-resistant plant varieties | $4M | 93 mo ago | Deadpooled | 2 | — | — | 10 patents Intragenic plant transformation vectors and recombinant DNA constructs for crop genetic improvement. | — |
| 11 | Avicena Systems Developer of biosecurity platform and hardware for pathogen testing | $3M | 28 mo ago | Funding Raised | 20 | Tony Fitzgerald Co-Founder & CEO | — | 22 patents High-throughput bioassay and pathogen/genetic screening instrumentation | 1 partnership |
| 12 | TGR BioSciences Specializes in immunoassay technology | $2M | 250 mo ago | Acquired | 11 | — | WordPressMySQLPHP+7 | 48 patents Multiplexed point‑of‑care diagnostic assays using lateral flow and substrate technologies | — |
| 13 | Gelomics Manufacturer of extracellular matrix for research purpose | $2M | 23 mo ago | Seed | 9 | Travis Klein Co-Founder | — | — | — |
| 14 | Vectus Biosystems Develops drug discovery platform | $2M | 43 mo ago | Public | — | Karen Duggan Founder & CEO | — | 258 patents Small-molecule therapeutics targeting organ fibrosis (kidney, liver, lung, hypertension). | — |
| 15 | fertilis Fertilis is a company that make in vitro fertilization (IVF) less stressful and more successful for patients… | $2M | 53 mo ago | Seed | 14 | — | — | — | — |
| 16 | Solvanix Provides technology for improving stability and reducing the aggregation of fully human antibodies | $2M | 137 mo ago | Deadpooled | — | Daniel Christ Founder & CSO | — | — | — |
| 17 | Tiny Bright Things Provider of microscopy tools for image and measurement | $2M | 43 mo ago | Seed | 5 | Raymond Dagastine Co-Founder & CEO | — | — | — |
| 18 | Fitgenes Personalised genome-based healthcare and wellness | $1M | 144 mo ago | Late Stage | 6 | Paul Beaver Co-Founder & CSO | Cart FunctionalityWooCommerceWordPress+36 | — | — |
| 19 | Zip Diagnostics Developer of molecular diagnostic tests and instruments for infectious diseases | $750K | 62 mo ago | Funding Raised | — | Jack Richards Co-Founder | Wix eCommerceCart FunctionalityWix+20 | 7 patents Rapid point‑of‑care lateral flow diagnostic testing for biological and environmental samples | — |
| 20 | MiniFAB Developing and Manufacturing Polymer Micro-Engineered Products | $102K | 104 mo ago | Acquired | 150 | — | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Australia
#1
Series C · Melbourne, Victoria · founded 2010 · 27 employees$23.6Mraised▾
PolyActiva has developed a platform technology for slow-release, site-specific drug delivery. Upon the application of the treatment, complete erosion of the implant occurs leaving no residue following drug release. This technology can be used to produce new biomedical products, drug-delivery devices and device components that enable delivery of drugs directly to the affected organ or treatment site. They are produced from a proprietary drug-polymer conjugate technology. Products are being developed for glaucoma, endophthalmitis, and osteoarthritis.
- May 2025Series C$25.7M
- Sep 2018Series B$11.5M
- Feb 2013Series B$9.5M
- Jan 2011Series A—
#2
Seed · Kelvin Grove, Queensland · founded 2018 · 9 employees$2.2Mraised▾
Manufacturer of extracellular matrix for research purpose. The product Luna gel is a photocrosslinkable extracellular matrix based on chemically-modified pharmaceutical grade gelatin. It retains the intrinsic cell-instructive bioactivity of natural ECMs facilitating cell attachment, proliferation, differentiation, migration, and proteolytic degradation. It has applications in cell attachment and proliferation, stem cell culture and differentiation, mechanotransduction assays, cancer spheroid assays.
- Jul 2024Seed$2.2M
#3
Public · Armadale, Western Australia · founded 1998 · 2 employees$32.2Mraised▾
Cynata Therapeutics is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale.
- Sep 2022Grant (prize money)$1M
- Dec 2020Post IPO$11.2M
- Oct 2019Grant (prize money)$34.1K
- Dec 2018Grant (prize money)—
#4
Series B · Sydney, New South Wales · founded 2013 · 90 employees$50Mraised▾
Operator of a bioprinting platform intended to help accelerate cancer research, drug discovery, and develop regenerative medicine. The company's digital 3D bioprinting technology allows rapid fabrication of living biological structures to accelerate the discovery of drugs for cancer and other diseases, enabling biomedical companies with an efficient bioprinting tool of 3D cell-based assays for research.
#5
Funding Raised · Perth, Western Australia · founded 2020 · 20 employees$3Mraised▾
Developer of biosecurity platform and hardware for pathogen testing. The company has developed a technology for testing pathogens. They created the Avicena Sentinel, a molecular diagnostics platform with an hourly screening capacity of thousands of samples. Additionally, they are engaged in the development of microLED-based ultra-low energy optical links.
- Feb 2024Grant (prize money)$3M
#6
Public · Perth, Western Australia · founded 1999$23.9Mraised▾
Developer of oro-mucosal drug delivery technology for treating multiple diseases. The company utilizes its proprietary OroMist, an oro-mucosal drug delivery technology to develop drugs that improve the health and lifestyle of patients. It offers ZolpiMist, an oral spray of zolpidem for insomnia; ArTiMist, a sub-lingual spray in the development stage for the treatment of malaria in children. The product pipeline also includes oral sprays of sumatriptan for migraine (SUD-001), ondansetron for chemotherapy-induced nausea and vomiting (SUD-002), sildenafil for erectile dysfunction (SUD-003) and PAH (SUD-004), and midazolam for pre-procedural anxiety (SUD-005).
- Jun 2021Post IPO$3.6M
- Dec 2020Post IPO$2.7M
- Aug 2020Post IPO$4.1M
- Nov 2013Post IPO$5.6M
#7
Acquired · Sydney, New South Wales · founded 2003 · 5 employees$14.7Mraised▾
Elastagen is a clinical stage medical company with a pipeline of formulation products based on the human protein tropoelastin.The company was founded after the acquisition of the Elastin technology from its founding scientist Prof Weiss (who is also the company's Lead Scientific Advisor) and his team at the University of Sydney. The Elastin technology offers a new pathway to produce a synthetic, identical and recombinant version of the naturally found "tropoelastin", the building blocks of elastin, a critical component in tissues responsible for the ability of lungs, skin, arteries and other elastic ligaments to stretch and recoil. The company claims that it is the first and only provider of commercial cGMP clinical grade human tropoelastin which can be used to support cell growth and tissue repair. Elastagen also claims the recombinant tropoelastin has an ideal biocompatibility profile and no immune rejection problems. Currently, the company is conducting pivotal clinical studies an injectable dermo-aesthetic product that supposedly restores the elasticity of the skin. In addition, it is investigating solutions for Atrophic Scars, Scar Revision and wound healing. Elastagen claims
- Oct 2016Grant (prize money)$4M
- Jun 2016Series B$744.8K
- Jan 2016Series B$9.2M
- Jul 2013Grant (prize money)$2M
#8
Public · Rosebery, New South Wales · founded 2005$2Mraised▾
Vectus Biosystems has developed a platform technology for drug discovery and development. It has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties. Additionally, the company's wholly-owned subsidiary, Accugen Pty Limited has designed and developed Accugen, a platform comprising of reagents and software that quantify qPCR reactions. It also holds patents around the Vasoactive Intestinal Peptide (VIP) and its fragments as a therapeutic candidate to treat cardiovascular fibrosis and systolic blood pressure. Vectus licenses its technology and intends to remain a research and development company.
- Nov 2022Post IPO$2M
#9
Seed · Melbourne, Victoria · founded 2020 · 5 employees$1.5Mraised▾
Provider of microscopy tools for image and measurement. The company offers Halo Element is a microscope attachment that enables imaging and measurement down to the scale of viruses, drug particles, and nanotubes.
- Nov 2022Seed$1.5M
#10
Funding Raised · Serpentine, Western Australia · founded 2001$4Mraised▾
Developer of biomarker panels and assays for disease assessment and detection. It focuses on developing biomarker panels for sleep disorders assessment at the point-of-care. Additionally, it develops novel alcohol biomarkers in whole blood. The company also creates biomarkers for staging Alzheimer's disease. Furthermore, it develops point-of-care assays for diabetes auto-antibody detection. It also researches protective antibody responses for an adjuvanted HIV vaccine.
- May 2020Grant (prize money)$1.7M
- Aug 2016Grant (prize money)$400K
- Apr 2016Grant (prize money)$222.8K
- Jan 2016Grant (prize money)$222.7K
#11
Public · Darlinghurst, New South Wales · founded 2001$10.7Mraised▾
Genetic Signatures develops and markets diagnostic reagents and kits for pathogen detection. Its proprietary 3Base technology uses the bisulfite method to enable pathogen detection by differentiating between methylated and unmethylated cytosine residues. Its flagship range of products EaasyScreen allows for the easy multiplexing of tests and is applicable for both DNA and RNA.
- Sep 2016Post IPO$10.7M
#12
Seed · Adelaide, South Australia · founded 2019 · 14 employees$2Mraised▾
Developer of vitro fertilization technology designed to automate cell culture with micro medical devices. The company's technology standardizes and automates the IVF process to protect the embryo and changes automated subtle to the nutritive composition of the formulated solutions, enabling medical professionals to grow the embryo inside its own patented micro-3D printed pod providing the most optimized growth environment ever developed.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.